–    TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) –    For children aged 5-11 years TransCon CNP demonstrated a change from baseline AGV superior to placebo with LS mean treatment difference of 1.78 cm/year at Week 52 (p<0.0001) –    Other endpoints supportive that TransCon CNP may provide benefits beyond linear growth –    TransCon CNP was generally well-tolerated, with low frequency of injection site reactions (0.41 events per pa ...